Overview
- OpenAI publicly unveiled the Rosalind Biodefense program to apply its frontier AI to pandemic preparedness and biodefense, and released a specialized life‑sciences model called GPT‑Rosalind.
- The program offers sponsored or trusted access to GPT‑Rosalind for qualified developers and select U.S. government and allied teams to accelerate applied work such as early detection, epidemiological modeling and therapeutic design.
- OpenAI is expanding partnerships with national labs and public‑health institutions, including Los Alamos, Lawrence Livermore and Johns Hopkins Applied Physics Laboratory, to evaluate safety and run pilot projects using the model.
- The company has also backed commercial players in the space, with reporting of a $30 million seed investment in Valthos joined by Lux Capital and Founders Fund, signaling growing VC interest in AI‑driven biosecurity.
- OpenAI says the rollout builds on internal preparedness work, including model safety assessments and a Preparedness Framework, while early participants such as Fourth Eon Biosecurity will pilot AI‑native screening and countermeasure workflows.